Standard Glass Lining Technology Limited’s Initial Public Offering (IPO) is generating significant buzz. The IPO, open from January 6th to 8th, 2025, aims to raise ₹410.05 crore. This includes a fresh issue of ₹210 crore and an offer for sale of ₹200.05 crore. The price band is set at ₹133-₹140 per share, with a minimum lot size of 107 shares costing ₹14,980.

The company, established in 2012, specializes in manufacturing technical equipment for the pharmaceutical and chemical sectors. Their product range includes glass-lined, stainless steel, and nickel-alloy equipment, along with PTFE-lined piping and fittings. Standard Glass Lining Technology boasts a diverse client base, including 30 of the approximately 80 pharmaceutical and chemical companies listed in the NSE 500 Index (as of June 30, 2024). The company’s strong financials show a 10% revenue increase and a 12% rise in profit after tax (PAT) between FY23 and FY24.

As of January 4th, 2025, the grey market premium (GMP) stood at ₹88 per share. While the GMP is not an indicator of the listing price, it reflects market sentiment. Analysts at Anand Rathi have given a “Subscribe-Long Term” recommendation, noting the company’s P/E ratio of 43.01x at the upper price band, along with an EV/EBITDA of 30.08x and a post-issue market cap of ₹27,928 million. The net proceeds from the IPO will be utilized for capital expenditure, debt repayment, strategic investments, and general corporate purposes.

Investors should carefully consider the company’s financials, growth prospects, and risks before making any investment decisions. The IPO’s success will depend on various factors, including market conditions and investor demand. Remember, the grey market premium (GMP) is purely speculative and should not be considered a reliable predictor of listing price. Consult with a financial advisor before investing in any IPO.